NCT06202417View on ClinicalTrials.gov

Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study

CompletedOBSERVATIONAL
Enrollment

520

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

June 30, 2022

Study Completion Date

December 25, 2023

Conditions
Colorectal CancerRefractory Colorectal CancerMetastatic Colorectal Cancer
Interventions
DRUG

Fruquintinib

an oral tyrosine kinase inhibitor (TKI)

Trial Locations (1)

200032

Zhongshan Hospital, Fudan University, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT06202417 - Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study | Biotech Hunter | Biotech Hunter